Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean E Collins

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Bulletin of the World Health Organization|July 15, 2015
Tuberculosis in the aftermath of the 2010 earthquake in HaitiSerena P Koenig, Vanessa Rouzier, Stalz Charles Vilbrun, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 16, 2020
Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency VirusPaul E Sax, Jürgen K Rockstroh, Anne F Luetkemeyer, et al.
The Lancet. HIV|May 10, 2019
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trialHans-Jürgen Stellbrink, José R Arribas, Jeffrey L Stephens, et al.
The Lancet. HIV|May 10, 2019
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trialDavid A Wohl, Yazdan Yazdanpanah, Axel Baumgarten, et al.
The Journal of Infectious Diseases|April 3, 2025
Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or ZinlirvimabJoseph J Eron, Paul P Cook, Megha L Mehrotra, et al.
The Lancet. Microbe|February 20, 2026
Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 studyOnyema Ogbuagu, Aditya Gaur, James H McMahon, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2021
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label StudyDebbie Hagins, Princy Kumar, Michael Saag, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 10, 2021
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 TrialsChloe Orkin, Faiza Ajana, Cissy Kityo, et al.
Journal of the International AIDS Society|July 8, 2021
Long-term mortality after tuberculosis treatment among persons living with HIV in HaitiYvetot Joseph, Zhiwen Yao, Akanksha Dua, et al.
Open Forum Infectious Diseases|October 6, 2016
A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected RwandansSean E Collins, Philip M Grant, Francois Uwinkindi, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Bulletin of the World Health Organization|July 15, 2015
Tuberculosis in the aftermath of the 2010 earthquake in HaitiSerena P Koenig, Vanessa Rouzier, Stalz Charles Vilbrun, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 16, 2020
Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency VirusPaul E Sax, Jürgen K Rockstroh, Anne F Luetkemeyer, et al.
The Lancet. HIV|May 10, 2019
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trialHans-Jürgen Stellbrink, José R Arribas, Jeffrey L Stephens, et al.
The Lancet. HIV|May 10, 2019
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trialDavid A Wohl, Yazdan Yazdanpanah, Axel Baumgarten, et al.
The Journal of Infectious Diseases|April 3, 2025
Lenacapavir Plus Two Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, for People With HIV-1 Highly Susceptible to Either Teropavimab or ZinlirvimabJoseph J Eron, Paul P Cook, Megha L Mehrotra, et al.
The Lancet. Microbe|February 20, 2026
Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 studyOnyema Ogbuagu, Aditya Gaur, James H McMahon, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 16, 2021
Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label StudyDebbie Hagins, Princy Kumar, Michael Saag, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 10, 2021
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 TrialsChloe Orkin, Faiza Ajana, Cissy Kityo, et al.
Journal of the International AIDS Society|July 8, 2021
Long-term mortality after tuberculosis treatment among persons living with HIV in HaitiYvetot Joseph, Zhiwen Yao, Akanksha Dua, et al.
Open Forum Infectious Diseases|October 6, 2016
A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected RwandansSean E Collins, Philip M Grant, Francois Uwinkindi, et al.
Pageof 3